PT-141

FDA Approved

Bremelanotide

Category
Sexual Health
Aliases
Bremelanotide, Vyleesi
Administration
Subcutaneous injection (approved), Intranasal (research)

Documented benefits

Tier 1 · Peer-reviewed / regulatory

Benefit categories

Sexual Health

PT-141's defining research application — the only FDA-approved peptide specifically for low sexual desire.

Increased libido

Enhances sexual desire by acting on melanocortin receptors in the brain, not on genital blood flow.

Improved sexual arousal

Increases central dopamine signaling in brain regions linked to motivation and reward.

Sexual desire restoration

Its FDA-approved indication — treating hypoactive sexual desire disorder through direct brain receptor activation.